India, July 11 -- Wockhardt is undertaking significant strategic realignment of its US business in line with its long-term vision to build a differentiated, innovation-driven pharmaceutical enterprise. As part of this transition, the Company has taken decision to exit the US generic pharmaceutical segment, paving the way for deeper focus and investment in its advanced product portfolio.This strategic reset aligns with Wockhardt's sharpened focus on building a future-ready business anchored in two key pillars:1. New Antibiotic Drug Discovery ' where Wockhardt has established a leadership position globally, with a strong pipeline of differentiated assets.2. Biologicals Portfolio in Insulin ' leveraging advanced technologies to address critica...